Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 7, 2015, Pages 1005-1011

  Benati, Marco ^a   Montagnana, Martina ^a   Danese, Elisa ^a   De Matteis, Giovanna ^a   Veneri, Dino ^b   Paviati, Elisa ^a   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

JAK2 V617F; miR 143; myeloproliferative neoplasms

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2; MICRORNA 143; MICRORNA; MIRN143 MICRORNA, HUMAN;

AGED; ALLELE; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; UPREGULATION; WORLD HEALTH ORGANIZATION; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER;

AGED; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; HUMANS; JANUS KINASE 2; MALE; MICRORNAS; MUTATION; MUTATION RATE; MYELOPROLIFERATIVE DISORDERS;

EID: 84930793312     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0858     Document Type: Article

References (50)

1. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112:2190-8.
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.
3. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed Leuk Lymphoma 2006;47:177-94.
4. Staerk J, Constantinescu SN. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAKSTAT 2012;1:184-90.
5. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010;1:979-93.
6. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Ann Rev Med 2008;59:213-22.
7. Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, et al. Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. PLoS One 2013;8:e74257.
8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
9. Cazzola M, Passamonti F. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica 2006;2:159.
10. Cetin G, Ozkan T, Turgut S, Ali Cikrikcioglu M, Cem Ar M, Ayer M, et al. Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Mol Biol Rep 2014;41:6737-42.
11. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
12. Zhan H, Cardozo C, Raza A. MicroRNAs in myeloproliferative neoplasms. Br J Haematol 2013;161:471-83.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;23;116:281-97.
14. Baek D, Vill J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
15. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007;35:1657-67.
16. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of micro-RNA in polycythemia vera. Haematologica 2008;93:1009-16.
17. Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, Martinelli G, et al.; AGIMM (AIRC-Gruppo Italiano Malattie Mielo proliferative) Investigators. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood 2011;117:6923-7.
18. Byon JC, Papayannopoulou T. MicroRNAs: allies or foes in erythropoiesis J Cell Physiol 2012;227:7-13.
19. Zhan H, Cardozo C, Yu W, Wang A, Moliterno AR, Dang CV, et al. MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis 2013;50:190-5.
20. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
21. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 2010;29:2161-4.
22. Fatica A, Fazi F. MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune. Int J Mol Sci 2013;14:20930-53.
23. Omer A, Yadav NK, Singh P, Singh RK. Hematological malignancies: role of miRNAs and their in silico aspects. Expert Rev Anticancer Ther 2013;13:1121-33.
24. Vasilatou D, Papageorgiou SG, Dimitriadis G, Pappa V. Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes. Epigenetics 2013;8:561-70.
25. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101:11755-60.
26. Undi RB, Kandi R, Gutti RK. MicroRNAs as haematopoiesis regulators. Adv Hematol 2013;2013:695754.
27. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2013;32:4806-13.
28. Wu D, Huang P, Wang L, Zhou Y, Pan H, Qu P. MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. Mol Med Rep 2013;8:626-30.
29. Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 2012;143:35-47.
30. Batliner J, Buehrer E, Fey MF, Tschan MP. Inhibition of the miR-143/145 cluster attenuated neutrophil differentiation of APL cells. Leuk Res 2012;36:237-40.
31. Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, et al. Micro-RNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 2012;11:23.
32. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
33. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) method. Methods 2001;25:402-8.
35. Fiedler SD, Carletti MZ, Christenson LK. Quantitative RT-PCR methods for mature microRNA expression analysis. Methods Mol Biol 2010;630:49-64.
36. Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 2014;123:2075-83.
37. Rosenthal A, Mesa RA. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Exp Opin Pharmacother 2014;15:1265-76.
38. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.
39. Park SH, Chi HS, Cho YU, Jang S, Park CJ. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res 2013;48:128-32.
40. Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, Sackmann F, et al. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 2009;14:323-30.
41. Zhou J, Ye Y, Zeng S, Zhou Y, Mao Z, Song X, et al. Impact of JAK2 V617F mutation on hemogram variation in patients with nonreactive elevated platelet counts. PLoS One 2013;8:e57856.
42. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
43. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al.; MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-9.
44. Raghavachari N, Liu P, Barb JJ, Yang Y, Wang R, Nguyen QT, Munson PJ. Integrated analysis of miRNA and mRNA during differentiation of human CD34+ cells delineates the regulatory roles of microRNA in hematopoiesis. Exp Hematol 2014;42:14-27.
45. Kent OA, McCall MN, Cornish TC, Halushka MK. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res 2014;42:7528-38.
46. Wang X, Hu G, Zhou J. Repression of versican expression by microRNA-143. J Biol Chem 2010;285:23241-50.
47. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705-10.
48. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009;28:1385-92.
49. Shen JZ, Zhang YY, Fu HY, Wu DS, Zhou HR. Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol Rep 2014;31:2035-42.
50. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-9.